Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 3, 2011, Pages 373-379

  Picazo, Juan J ^a   Betriu, Carmen ^a   Rodríguez Avial, Iciar ^a   Culebras, Esther ^a   López Fabal, Fátima ^a   Gómez, María ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Comparison between broth microdilution and Etest; Daptomycin activity; Glycopeptide tolerance; HGISA isolates; Staphylococci

Indexed keywords

BACTERIAL PROTEIN; CFR PROTEIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BROTH DILUTION; CFR GENE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; EPSILOMETER TEST; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPAIN; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; GLYCOPEPTIDES; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; SPAIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 79959223686     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.02.009     Document Type: Article

References (41)

1. Anastasiou DM, Morgan M, Ruane PJ, Steenbergen JN, Katz BD, Alder JD, Thorne GM In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates. Diagn. Microbiol. Infect. Dis. 2008, 61:339-342.
2. Bennett JW, Murray CK, Holmes RL, Patterson JE, Jorgensen JH Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 2008, 60:437-440.
3. Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int. J. Antimicrob. Agents 2007, 30:143-149.
4. Bourgeois I, Pestel-Caron M, Lemeland JF, Pons JL, Caron F Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci. Antimicrob. Agents Chemother. 2007, 51:740-743.
5. Campanile F, Bongiorno D, Borbone S, Falcone M, Giannella M, Venditti M, Stefani S In vitro activity of daptomycin against methicillin- and multi-resistant Staphylococcus haemolyticus invasive isolates carrying different mec complexes. Diagn. Microbiol. Infect. Dis. 2008, 61:227-231.
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing. 20th informational supplement. vol. 30, no. 1, M100-S20 2010, CLSI, Wayne, PA.
7. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed. vol 29, no. 2. M7-A8 2009, CLSI, Wayne, PA.
8. Cremniter J, Slassi A, Quincampoix JC, Sivadon-Tardy V, Bauer T, Porcher R, Lortat-Jacob A, Piriou P, Judet T, Herrmann JL, Gaillard JL, Rottman M Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections. J. Clin. Microbiol. 2010, 48:1428-1431.
9. Cubicin Package Insert Prescribing Information.pdf Available at, Accessed on February 2011. http://w.w.w.cubicin.com.
10. Cui L, Tominaga E, Neoh H, Hiramatsu K Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2006, 50:1079-4082.
11. Deresinski S Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 2009, 199:605-609.
12. Holmes RL, Jorgensen JH Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob. Agents Chemother. 2008, 52:757-760.
13. Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 2008, 32:378-385.
14. Jones RN Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 2006, 42(Suppl. 1):513-524.
15. Kehrenberg C, Schwarz S Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob. Agents Chemother. 2006, 50:1156-1163.
16. Leonard SN, Rossi KL, Newton KL, Rybak MJ Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antmicrob. Chemother. 2009, 63:489-492.
17. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 2008, 52:3315-3320.
18. Maniati M, Petinaki E, Kontos Maniatis AN, Spiliopoulou I, Petropoulou-Mylona D, Malamou-Lada H, Spaliara L, Koutsia-Carouzou C Rapid increase in numbers of Staphylococcus epidermidis strains with reduced susceptibility to teicoplanin in Greece. Int. J. Antimicrob. Agents 2005, 25:346-348.
19. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 2009, 199:619-624.
20. Mason EO, Lamberth LB, Hammerman WA, Hulten KG, Versalovic J, Kaplan SL Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J. Clin. Microbiol. 2009, 47:1628-1630.
21. May J, Shannon K, King A, French G Glycopeptide tolerance in Staphylococcus aureus. J. Antimicrob. Chemother. 1998, 42:189-197.
22. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Pelaez B, Andrade R, de la Torre MA, Fereres J, Sánchez-García M Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 2010, 50:821-825.
23. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, Khatib R Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 2009, 47:1640-1644.
24. National Committee for Clinical Laboratory Standards Methods for determining bactericidal activity of antimicrobial agents. Approved standard M26-A 1999, National Committee for Clinical Laboratory Standards, Wayne, PA.
25. Paiva RM, Mombach Pinheiro Machado AB, Zavascki AP, Barth AL Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus sp.: Evaluation of the broth microdilution and Etest methods. J. Clin. Microbiol. 2010, 48:4652-4654.
26. Perry JD, Jones AL, Gould FK Glycopeptide tolerance in bacteria causing endocarditis. J. Antimicrob. Chemother. 1999, 44:121-124.
27. Pfaller MA, Sader HS, Jones RN Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn. Microbiol. Infect. Dis. 2007, 57:459-465.
28. Picazo JJ, Betriu C, Culebras E, Rodríguez-Avial I, Gómez M, López F Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers. Diagn. Microbiol. Infect. Dis. 2009, 64:448-451. the VIRA Study Group.
29. Picazo JJ, Betriu C, Rodríguez-Avial I, Culebras E, Gómez M, López F Vigilancia de resistencias a los antimicrobianos: estudio VIRA 2006. Enferm. Infecc. Microbiol. Clin. 2006, 24:617-628. Grupo VIRA.
30. Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, Olsen KM Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in clinical methicillin-resistant S. aureus (MRSA) Isolates. J. Clin. Microbiol. 2011, 49:269-274.
31. Prakash V, Lewis JS, Jorgensen JH Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother. 2008, 52:4528.
32. Sader HS, Becker HK, Moet GJ, Jones RN Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 μg/mL isolated in the United States and European hospitals (2006-2008). Diagn. Microbiol. Infect. Dis. 2010, 66:329-331.
33. Sader HS, Jones RN Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn. Microbiol. Infect. Dis. 2009, 65:158-162.
34. Sader HS, Moet G, Jones RN Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007). J. Chemother. 2009, 21:500-506.
35. Sakoulas G, Moise-Broder PA, Schenta J, Forrest A, Moellering RC, Eliopoulos GM Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 2004, 42:2398-2402.
36. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, López J, Mensa J Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2008, 46:193-200.
37. Steinkraus G, White R, Friedrich L Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-2005. J. Antimicrob. Chemother. 2007, 60:788-794.
38. Traczewski MM, Katz BD, Steenbergen JN, Brown SD Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. Antimicrob. Agents Chemother. 2009, 53:1735-1738.
39. Trueba F, Garrabe E, Hadef R, Fabre R, Cavallo JD, Tsvetkova K, Chesneau O High prevalence of teicoplanin resistance among Staphylococcus epidermidis strains in a 5-year retrospective study. J. Clin. Microbiol. 2006, 44:1922-1923.
40. van Hal SJ, Wehrhahn MC, Barbagiannakos T, Mercer J, Chen D, Paterson DL, Gosbell IB Performance of various testing methodologies for detection of heteroresistant vancomycin intermediate Staphylococcus aureus (hVISA) in bloodstream isolates. J. Clin. Microbiol. 2011, 02:302-310. doi:10.1128/JCM.
41. Wang G, Hindler JF, Ward KW, Bruckner DA Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 2006, 44:3883-3886.